Hear from our expert during TIDES Europe 2019
During TIDES Europe 2019 (12-15 November, Amsterdam) our expert will present on optimizing analytical techniques for oligonucleotide development.
Learn how Intertek can support your oligonuclotide development from early stage characterisation to late-stage development and commercialisation. Arrange a meeting with one of our experts to discuss how to overcome your current analytical challenges, visit Stand #27 or attend our presentation discussing optimised techniques in analytical development.
TIDES EUROPE PRESENTATION:
Improving Separation and Maximising Throughput: Optimisation of LC-MS Analysis of Therapeutic Oligonucleotides
Wednesday 13 November, 12pm- 12.30pm
Magdalena Kiezel-Tsugunova, Senior Analyst, Intertek Pharmaceutical Services
Abstract: The chemical structure of the therapeutic oligonucleotide must be optimised to ensure bioavailability and clinical efficacy. Hence, the characterisation of identity, assay and impurity profile of therapeutic oligonucleotides is crucial for the drug development and assessment of contaminants and drug safety. The more efficient and robust analytical methods are required to support clinical testing and drug registration.
If you would like a copy of the presentation, please send a request now to receive the slides after the event.
Case Study: Identification Testing by Accurate Mass and MS/MS Sequencing
Case Study: Oligonucleotide Identification, Assay and Impurities
Case Study: Determination of Melting Temperature for Oligonucleotide Duplexes using NMR
Article Download: Analytical challenges in the oligonucleotide characterisation
White Paper: Analytical Strategies for Quality Control of Oligonucleotide Therapeutics
With a growing global development pipeline of oligonucleotide therapeutics to treat a variety of disease targets, overcoming the challenges of innovation, regulatory authorization, production and the inherent complexity of oligos is critical to success. Contact our experts in oligonucleotide analysis and bioanalysis, to discuss our regulatory-driven, phase-appropriate characterization and biophysical analysis in support of CMC programs which GMP and CMC laboratory services, pharmaceutical analysis, quality control analysis, elemental impurities, extractables and leachables, stability programs, inhalation drug development, method development and method validation will be available to review your challenges and discuss and how our unrivalled expertise can help you to accelerate the development timelines.
Need help or have a question?